6:20 PM
 | 
Oct 23, 2012
 |  BC Extra  |  Financial News

Gilead beats Street, raises guidance

Gilead Sciences Inc. (NASDAQ:GILD) increased its full-year sales guidance to $9.1-9.2 billion from $8.8-9.0 billion after reporting 3Q12 financial results on Tuesday that beat the Street's estimates. Non-GAAP diluted EPS for the quarter was $1,...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >